%0 Journal Article
%T A Case of Retinal Tear Associated with Use of Sorafenib
%A Kelly M. Gaertner
%A Stephen H. Caldwell
%A Osama E. Rahma
%J Frontiers in Oncology
%D 2014
%I Frontiers Media
%R 10.3389/fonc.2014.00196
%X Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhibitor, sunitinib. We report the first case of retinal tear possibly associated with sorafenib.
%K sorafenib
%K retinal tear
%K VEGFR inhibitor
%K angiogenesis inhibitor
%K hepatocellular carcinoma
%U http://www.frontiersin.org/Journal/10.3389/fonc.2014.00196/abstract